Home › Chronic Myelomonocytic Leukemia
Pag-aaral pangklinika para sa Chronic Myelomonocytic Leukemia na nagre-recruit sa U.S.
44 pag-aaral para sa Chronic Myelomonocytic Leukemia ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX16 pag-aaral
- Seattle, WA10 pag-aaral
- Boston, MA8 pag-aaral
- Rochester, MN6 pag-aaral
- Mountain View, CA6 pag-aaral
- New York City, NY6 pag-aaral
- Baldwin Park, CA6 pag-aaral
- Durham, NC5 pag-aaral
- Tampa, FL4 pag-aaral
- Portland, OR4 pag-aaral
- Columbus, OH4 pag-aaral
- Atlanta, GA4 pag-aaral
- Miami, FL4 pag-aaral
- Birmingham, AL4 pag-aaral
- Nashville, TN3 pag-aaral
- St. Louis, MO3 pag-aaral
- Charleston, SC3 pag-aaral
- Los Angeles, CA3 pag-aaral
Ayos sa estado
- Alabama4 pag-aaral
- Arizona3 pag-aaral
- California12 pag-aaral
- Florida8 pag-aaral
- Georgia4 pag-aaral
- Maryland3 pag-aaral
- Massachusetts8 pag-aaral
- Minnesota7 pag-aaral
- Missouri3 pag-aaral
- New York8 pag-aaral
- North Carolina5 pag-aaral
- Ohio5 pag-aaral
- Oregon4 pag-aaral
- Pennsylvania4 pag-aaral
- South Carolina3 pag-aaral
- Tennessee3 pag-aaral
- Texas18 pag-aaral
- Washington10 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT06523556Personalized NK Cell Therapy in CBT
Nagre-recruitPhase 2
Edad 15 hanggang 80 · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT02727803Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT06904066Therapeutic RSK1 Targeting in Myeloid Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 21, 2026 · NCT07379125Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 20, 2026 · NCT06543381Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 15, 2026 · NCT06691217Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 9, 2026 · NCT07128381Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 7, 2026 · NCT07143669A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT04256317CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT03896269Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT04140487Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT03418038CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04375631(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04996875Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT03683433A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06566742Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT03383575Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07249346Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT07033598TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Nagre-recruitPhase 1
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT07302776Pacritinib in CMML
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT06159491Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Nagre-recruitPhase 2/3Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT04708054Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Nagre-recruitPhase 1/2
Edad 12 hanggang 80 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT05092451Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT07046078Registry of Older Patients With Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 65 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT01137825Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.